Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies

作者：Yining Zhao, Yumei Li, Xiaoqiong Wu, Li Li, Jiayu Liu, Yanlan Wang, Yue Liu, Qing Li, Zhong Wang · 发表于：Cancer Biology & Therapy · 年份：2019 · DOI：10.1080/15384047.2019.1665953 · 被引用次数：30 · 研究领域：Monoclonal and Polyclonal Antibodies Research、Protein purification and stability、Glycosylation and Glycoproteins Research

CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.